NEUROTROPHIC TYROSINE RECEPTOR KINASE INHIBITORS IN THE MANAGEMENT OF SOLID TUMOURS: A SYSTEMATIC REVIEW AND META-ANALYSIS (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 01 - 153; Pres time: Sep 16, 2026; Location: Exhibition Area; "The agents investigated were larotrectinib, entrectinib, repotrectinib, and merestinib. TRK inhibitors demonstrates substantial clinical activity and are a promising therapeutic strategy for pediatric solid tumours harboring NTRK fusions. However, these therapies present substantial toxicity and there is a need of prospective trials evaluating survival to explore their efficacy."
Retrospective data • Review • Oncology • Solid Tumor • NTRK
|
|
Virna Correia1; Oleksandr Teteria2; Marcelo Caiafa3; Vitor Vidal4; Maria Merighi5; Ana Vieira6
|